Role of S-adenosyl-L-methionine in the treatment of depression: A review of the evidence

American Journal of Clinical Nutrition

Volumn 76, Issue 5, 2002, Pages

  Mischoulon, David ^a   Fava, Maurizio ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Alternative treatments; Antidepressants; Depression; Natural treatments; S adenosyl L methionine; SAMe

Indexed keywords

ANTIDEPRESSANT AGENT; IMIPRAMINE; METHIONINE; NEUROTRANSMITTER; S ADENOSYLMETHIONINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ALTERNATIVE MEDICINE; ALZHEIMER DISEASE; ANXIETY DISORDER; APPETITE DISORDER; ARTICLE; BIPOLAR DISORDER; CLINICAL TRIAL; CONSTIPATION; DEPRESSION; DOSE RESPONSE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HYPOMANIA; INSOMNIA; LIVER TOXICITY; MANIA; NAUSEA; NERVOUSNESS; SWEAT GLAND DISEASE; VERTIGO; XEROSTOMIA;

EID: 0036829068     PISSN: 00029165     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcn/76.5.1158s     Document Type: Article

References (40)

1. Pincus HA, Pettit AR. The societal costs of chronic major depression. J Clin Psychiatry 2001;62(suppl):5-9.
2. Kendler KS, Thornton LM, Prescott CA. Gender differences in the rates of exposure to stressful life events and sensitivity to their depressogenic effects. Am J Psychiatry 2001;158:587-93.
3. Fava M, Davidson KG. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am 1996;19:179-200.
4. Fava M, Kaji K. Continuation and maintenance treatments of major depressive disorder. Psychiatr Ann 1994;24:281-90.
5. Eisenberg DM, Kessler RC, Foster C, Norlock FE, Calkins DR, Delbanco TL. Unconventional medicine in the United States: Prevalence, costs, and patterns of use. N Engl J Med 1993;328: 246-52.
6. Mischoulon D, Rosenbaum JF. The use of natural medications in psychiatry. A commentary. Harv Rev Psychiatry 1999;6:279-83.
7. Krippner S. A cross cultural comparison of four healing models. Altern Ther Health Med 1995;1:21-9.
8. National Institutes of Health, Office of Alternative Medicine, Practice and Policy Guidelines Panel. Clinical practice guidelines in complementary and alternative medicine. An analysis of opportunities and obstacles. Arch Fam Med 1997;6:149-54.
9. Ernst E. Harmless herbs? A review of the recent literature. Am J Med 1998;104:170-8.
10. Spillmann M, Fava M. S-adenosyl-methionine (ademethionine) in psychiatric disorders. CNS Drugs 1996;6:416-25.
11. Alpert JE, Mischoulon D. One-carbon metabolism and the treatment of depression: roles of S-adenosyl methionine (SAMe) and folic acid. In: Mischoulon D, Rosenbaum J, eds. Natural Medications for Psychiatric Disorders: Considering the Alternatives. Philadelphia: Lippincott Williams & Wilkins, 2002:44.
12. Alpert JE, Mischoulon D, Nierenberg AA, Fava M. Nutrition and depression: Focus on folate. Nutrition 2000;16:544-6.
13. Fava M, Borus JS, Alpert JE, et al. Folate, B 12, and homocysteine in major depressive disorder. Am J Psychiatry 1997;154:426-8.
14. Bottiglieri T, Godfrey P, Flynn T, Carney MWP, Toone BK, Reynolds EH. Cerebrospinal fluid S-adenosylmethionine in depression and dementia: Effects of treatment with parenteral and oral S-adenosylmethionine. J Neurol Neurosurg Psychiatry 1990;53:1096-8.
15. Bell KM, Potkin SG, Carreon D, Plon L. S-denosylmethionine blood levels in major depression: Changes with drug treatment. Acta Neurol Scand Suppl 1994;154:15-8.
16. Bottiglieri T, Chary TK, Laundy M, et al. Transmethylation in depression. Ala J Med Sci 1988;25:296-301.
17. Matthysse S, Baldessarini RJ. S-adenosylmethionine and catechol-O-methyl-transferase in schizophrenia. Am J Psychiatry 1972;128: 1310-2.
18. Tolbert LC. MAT kinetics in affective disorders and schizophrenia. An account. Ala J Med Sci 1988;25:291-6.
19. Bressa GM. S-adenosyl-L-methionine (SAMe) as antidepressant: Meta-analysis of clinical studies. Acta Neurol Scand 1994;154 (suppl):7-14.
20. Mantero M, Pastorino P, Carolei A, Agnoli A. Studio controllato in doppio cieco (SAMe-imipramina) nelle sindromi depressive. [Controlled double-blind study (SAMe-imipramine) in depressive syndrome.] Minerva Med 1975;66:4098-101 (in Italian).
21. Miccoli L, Porro V, Bertolino A. Comparison between the antide-pressant activity of S-adenosyl-L-methionine (SAMe) and that of some tricyclic drugs. Acta Neurol (Napoli) 1978;33:243-55.
22. Del Vecchio M, Iorio G, Cocorullo M, Vacca L, Amati A. Has SAMe (Ado-Met) an antidepressant effect? A preliminary trial versus chlorimipramine. Riv Sper Freniatr 1978;102:344-58.
23. Monaco P, Quattrocchi F. Studio degli effetti antidepressivi di un transmetilante biologico (S-adenosil-metionina - SAMe). (Study of the antidepressant effect of a biological transmethylator (S-adenosylmethionine - SAMe.) Riv Neurol 1979;49:417-39 (in Italian).
24. Calandra C, Roxas M, Rapisarda V. Azione antidepressiva della SAMe a paragone della clorimipramina. Ipotesi interpretative del meccanismo d'azione. (Andidepressant action of SAMe compared to that of clomipramine. Interpretive hypothesis of the mechanism of action.) Minerva Psichiatr 1979;20:147-52 (in Italian).
25. Kufferle B, Grunberger J. Early clinical double-blind study with S-adenosyl-L-methionine: A new potential antidepressant. In: Costa E, Racagni G, eds. Typical and Atypical Antidepressants. New York: Raven Press, 1982:175-80.
26. Bell KM, Plon L, Bunney WE Jr, Potkin SG. S-adenosylmethionine treatment of depression: A controlled clinical trial. Am J Psychiatry 1988;145:1110-4.
27. Janicak PG, Lipinski J, Davis JM, et al. S-Adenosylmethionine in depression: A literature review and preliminary report. Ala J Med Sci 1988;25:306-13.
28. Fava M, Giannelli A, Rapisarda V, Patralia A, Guaraldi GP. Rapidity of onset of the antidepressant effect of parenteral S-adenosyl-L-methionine. Psychiatry Res 1995;56:295-7.
29. Alvarez E, Udina C, Guillamat R. Shortening of latency period in depressed patients treated with SAMe and other antidepressant drugs. Cell Biol Rev 1987;S1:103-10.
30. Berlanga C, Ortega-Soto HA, Ontiveros M, Senties H. Efficacy of S-adenosyl-L-methionine in speeding the onset of action of imipramine. Psychiatry Res 1992;44:257-62.
31. Fontanari D, DiPalma C, Giorgetti G, et al. Effects of S-adenosyl-L-methionine on cognitive and vigilance functions in elderly. Curr Ther Res 1994;55:682-9.
32. Reynolds EH, Carney MWP, Toone BK, et al. Transmethylation and neuropsychiatry. Cell Biol Rev 1987;2:93-102.
33. Cerutti R, Scichel MP, Perin M, et al. Psychological distress during puerperium: A novel therapeutic approach using S-adenosylmethionine. Curr Ther Res 1993;53:707-16.
34. Lo Russo A, Monaco M, Pani A, et al. Efficacy of S-adenosyl methionine in relieving psychologic distress associated with detoxification on opiate abusers. Curr Ther Res 1994;55:905-13.
35. Agricola R, Dalla Verde G, Urani R, et al. S-adenosyl-L-methionine in the treatment of major depression complicating chronic alcoholism. Curr Ther Res 1994;55:83-92.
36. Di Rocco A, Rogers JD, Brown R, Werner P, Bottiglieri T. S-Adenosyl-methionine improves depression in patients with Parkinson's disease in an open-label clinical trial. Mov Disord 2000;15:1225-9.
37. Martínez-Chantar ML, García-Trevijano ER, Latasa MU, et al. Importance of a deficiency in S-adenosyl-L-methionine synthesis in the pathogenesis of liver injury. Am J Clin Nutr 2002;76(suppl): 1177S-82S.
38. Rosenbaum JF, Fava M, Falk WE, et al. The antidepressant potential of oral S-adenosyl-L-methionine. Acta Psychiatr Scand 1990; 81:432-6.
39. Carney MWP, Chary TNK, Bottiglieri T. Switch mechanism in affective illness and oral S-adenosylmethionine (SAM). Br J Psychiatry 1987;150:724-5.
40. Carney MW, Martin R, Bottiglieri T, et al, Switch mechanism in affective illness and S-adenosylmethionine. Lancet 1983;1:820-1.